Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Rezolute, Inc. (OCTQB:RZLT) has announced a $41 million private placement financing led by CAM Capital, with participation from other notable investors. The funds will advance RZ358 for congenital hyperinsulinism, initiate a Phase 1 study for RZ402 targeting diabetic macular edema, and cover general corporate purposes, including a potential Nasdaq listing. The company plans to issue approximately 124 million shares at $0.33 each, accompanied by warrants. A reverse stock split of 1:50 is also anticipated to meet Nasdaq requirements.